GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (STU:8BT) » Definitions » Revenue per Share

BriaCell Therapeutics (STU:8BT) Revenue per Share : €0.00 (TTM As of Jan. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BriaCell Therapeutics Revenue per Share?

BriaCell Therapeutics's revenue per share for the three months ended in Jan. 2024 was €0.00. BriaCell Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Jan. 2024 was €0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for BriaCell Therapeutics's Revenue per Share or its related term are showing as below:

STU:8BT's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.5
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

BriaCell Therapeutics Revenue per Share Historical Data

The historical data trend for BriaCell Therapeutics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Revenue per Share Chart

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BriaCell Therapeutics's Revenue per Share

For the Biotechnology subindustry, BriaCell Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's PS Ratio falls into.



BriaCell Therapeutics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

BriaCell Therapeutics's Revenue Per Share for the fiscal year that ended in Jul. 2023 is calculated as

Revenue Per Share (A: Jul. 2023 )=Revenue (A: Jul. 2023 )/Shares Outstanding (Diluted Average) (A: Jul. 2023 )
=0/15.620
=0.00

BriaCell Therapeutics's Revenue Per Share for the quarter that ended in Jan. 2024 is calculated as

Revenue Per Share (Q: Jan. 2024 )=Revenue (Q: Jan. 2024 )/Shares Outstanding (Diluted Average) (Q: Jan. 2024 )
=0/15.982
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BriaCell Therapeutics  (STU:8BT) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


BriaCell Therapeutics Revenue per Share Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (STU:8BT) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

BriaCell Therapeutics (STU:8BT) Headlines

No Headlines